Affymetrix Launches DNA Copy Number Service for Difficult FFPE Samples in Cancer Research
April 19 2010 - 6:00AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the
Affymetrix® MIP Copy Number Service, designed for cancer
researchers using challenging FFPE samples. With the MIP Copy
Number Service, scientists can now obtain high-quality
allele-specific copy number data from FFPE samples. The service is
available for research use only exclusively through the Affymetrix®
Research Services Laboratory (ARSL).
DNA obtained from FFPE samples is often of insufficient quantity
and too degraded for many array platforms, resulting in low sample
pass rates. A recent article in the journal BMC Cancer1
demonstrated that the MIP copy number assay generates high-quality
data from ovarian FFPE samples with starting material as low as 75
nanograms (ng) and a sample pass rate greater than 90 percent. In a
separate study in the journal Cancer Research2, researchers used
MIP technology to distinguish high copy number changes within
specific grades of pediatric brain cancer, even with samples stored
for more than 20 years.
The Affymetrix MIP Copy Number Service has been successfully
used by leading cancer research institutes, including the M. D.
Anderson Cancer Center, the University of California, San
Francisco, and the Huntsman Cancer Institute at the University of
Utah.
"Translational laboratories are having tremendous success using
the Affymetrix® MIP 330K Cancer Panel,” said Andy Last, Chief
Commercial Officer of Affymetrix. “The broad dynamic range and high
resolution of our MIP technology allows the identification of copy
number values of 10 and higher, as demonstrated in the journal
Cancer Research2,” added Last. “Additionally, in the journal Cancer
Genetics and Cytogenetics3, the MIP assay identified both novel
copy number aberrations (CNAs) and previously described CNAs in
childhood leukemia samples.”
Previous studies have indicated that genomic instability is
associated with tumor grade, tumor development, and disease
progression. Because the MIP copy number application offers both
allele and copy number data on a single platform, researchers now
have a more comprehensive tool to evaluate risk factors for the
early stages of cancer and disease relapse. Pairing allele
information with copy number calls also enables a more in-depth
analysis of cancer, including copy-neutral loss of heterozygosity,
levels of normal-tumor contamination, and preferential allele
amplification.
“Cancer researchers are unlocking the full potential of millions
of archived FFPE samples using MIP copy number technology,” said
Kevin King, President and CEO of Affymetrix. “Leading cancer
researchers can now link copy number data with clinical data from
these archived resources. This is the tremendous advantage of the
MIP assay and will help researchers yield discoveries that could
ultimately improve cancer diagnosis and categorization of patients,
and thus lead to more targeted and individualized strategies for
the treatment of cancer.”
For more information about the Affymetrix MIP Copy Number
Service, please visit
www.affymetrix.com/estore/browse/products.jsp?productId=prod150008
1Press J. Z., et al. Ovarian carcinomas with genetic and
epigenetic BRCA1 loss have distinct molecular abnormalities. BMC
Cancer 8:17 (2008).
2Schiffman J. D., et al. Oncogenic BRAF mutation with CDKN2A
inactivation is characteristic of a subset of pediatric malignant
astrocytomas. Cancer Research 70(2):512-9 (2010).
3Schiffman J. D., et al. Molecular inversion probes reveal
patterns of 9p21 deletion and copy number aberrations in childhood
leukemia. Cancer Genetics and Cytogenetics 193(1):9-18 (2009).
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government and nonprofit research institutes. More than
1,900 systems have been shipped around the world and more than
21,000 peer-reviewed papers have been published using the
technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Cleveland, Ohio, and Singapore. The
company has about 1,000 employees worldwide and maintains sales and
distribution operations across Europe and Asia. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies,” or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2009, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024